Industry news that matters to you.  Learn more

Roche Receives FDA Approval for VENTANA ALK (D5F3) CDx Assay to Identify Lung Cancer Patients Eligible for Treatment with Roche’s ALECENSA (alectinib)

Roche recently announced it has obtained US Food and Drug Administration (FDA) approval for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Roche medicine ALECENSA® (alectinib). The VENTANA ALK (D5F3) CDx Assay is the only test FDA-approved as a companion diagnostic for ALECENSA.

Biognosys Announces a Technological Breakthrough in the Development of Its Next-Generation Proteomics Workflow

Biognosys AG announced today a breakthrough in the development of its next generation proteomics technology that helps scientists to understand complex biological processes. For the first time, Biognosys’ data-independent acquisition (DIA) mass spectrometry workflow has identified and quantified more peptides than sequentially possible with data dependent acquisition (DDA) on a Thermo Scientific™ Q Exactive™ HF. The DIA method now provides a clear path to the ultimate life science community goal – to quantify every protein, the complete proteome, in a biological sample of interest. The results of the study have recently been published in the journal Molecular and Cellular Proteomics.

An Updated Biomarker Commons Website

Today, we’ve launched an updated BiomarkerCommons.org website. We’ve kept the clean page style and introduce larger, easier-to-read fonts and a new layout optimized for all your mobile devices.

8 Questions about Biomarker Commons

Biomarker Commons launched just over three years ago with the goal of aggregating the latest biomarker and personalized medicine news.

Now, we really need your feedback. We’ve got 8 simple questions that should take you less than 5 minutes to complete. Please let us know how we’ve been doing and what we can do to improve our service.

NYAS Symposium Review: Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease

The New York Academy of Sciences (NYAS) symposium, Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease, was held last week Tuesday. About 150 people were in attendance consisting of a mix of academic and industrial researchers. [On a side note, the NYAS symposium office is located on the 40th floor of 7 World Trade Center and the views of New York city are spectacular.]